中光學(002189.SZ)半年度淨利潤預降0.55%-9.59%
格隆匯 7 月 7日丨中光學(002189.SZ)公佈,預計2020半年度歸屬於上市公司股東的淨利潤5000萬元至5500萬元,同比下降0.55%-9.59%。
受新冠肺炎疫情影響,一季度公司收入下降約24.89%,經營業績出現虧損。二季度以來,隨着國內疫情形勢逐步得到控制,以及國家一系列支持復工復產穩定經濟政策措施的出台,公司生產經營得以快速恢復;同時,公司適應後疫情時代產業結構的變化,積極採取措施進行產品及客户結構調整,二季度營業收入、利潤同比均有較大增長,經營業績得以恢復,上半年實現盈利。
上半年歸屬於上市公司股東的淨利潤中包含政府補助等非經常性損益,金額約1400萬-1500萬元(税前)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.